Antisoma announces promising preliminary phase II data for AS1404 in lung cancer
The lung cancer study is a multi-centre, randomised, controlled trial in patients being treated for the first time for locally advanced or metastatic non-small cell lung cancer. Enrollment was completed in August 2005, and the trial has included patients with both squamous and non-squamous lung cancers. Follow up of patients is continuing and Antisoma plans to present further data at medical congresses. These will include the final investigator-determined response rates, independently validated response rates and data on time to disease progression and survival. Disease progression data are expected during the first half of 2006.
AS1404 belongs to a class of drugs called vascular disrupting agents. These drugs selectively attack tumour blood vessels, giving them broad potential against solid cancers, which depend on their blood supply to survive and grow. Antisoma's lung cancer study is the first controlled trial of a vascular disrupting agent to report evidence of anti-cancer activity.
AS1404 is included in Antisoma's strategic oncology alliance with Roche.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.